Quanterix Appoints New Director

TL;DR

Quanterix adds Dr. Sarah Michaels to its board, effective Oct 2.

AI Summary

Quanterix Corporation announced on October 2, 2024, a change in its board of directors. Specifically, Dr. Sarah Michaels has been appointed as a new Class II director, effective immediately. This appointment is part of the company's ongoing efforts to strengthen its governance and strategic direction.

Why It Matters

The addition of a new director can signal strategic shifts or a focus on specific areas of expertise, potentially impacting the company's future performance and investor confidence.

Risk Assessment

Risk Level: low — This filing reports a routine board appointment, which typically carries low immediate risk.

Key Players & Entities

• Quanterix Corporation (company) — Registrant
• Dr. Sarah Michaels (person) — Newly appointed Class II director
• October 2, 2024 (date) — Effective date of appointment

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share QTRX The Nasdaq Glo
• $400,000 — isch received an equity award valued at $400,000 comprised of (i) 60% non-qualified stoc

Filing Documents

• qtrx-20241002.htm (8-K) — 26KB
• qtrx-20241002xex991.htm (EX-99.1) — 10KB
• 0001628280-24-042118.txt ( ) — 161KB
• qtrx-20241002.xsd (EX-101.SCH) — 2KB
• qtrx-20241002_lab.xml (EX-101.LAB) — 21KB
• qtrx-20241002_pre.xml (EX-101.PRE) — 12KB
• qtrx-20241002_htm.xml (XML) — 3KB

02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On October 2, 2024, the board of directors (the "Board") of Quanterix Corporation (the "Company") appointed Ivana Magovevi-Liebisch, Ph.D., J.D. to serve on the Board effective immediately. Dr. Magovevi-Liebisch will serve as a Class III director with a term that will expire at the Company's 2026 annual meeting of stockholders. Dr. Magovevi-Liebisch has also been appointed as a member of the Compensation Committee of the Board. There is no arrangement or understanding between Dr. Magovevi-Liebisch and any other person pursuant to which she was selected as a director of the Company, and there is no family relationship between Dr. Magovevi-Liebisch and any of the Company's other directors or executive officers. Dr. Magovevi-Liebisch does not have a material interest in any transaction that is required to be disclosed under Item 404(a) of Regulation S-K. In accordance with the Company's amended and restated non-employee director compensation policy (the "Policy"), Dr. Magovevi-Liebisch received an equity award valued at $400,000 comprised of (i) 60% non-qualified stock options to purchase the Company's common stock at an exercise price equal to the closing price of the common stock on October 2, 2024 and (ii) 40% RSUs. The options vest over three years from the date of grant, with one-third vesting on the first anniversary and the remainder vesting over the following two years in 24 successive equal monthly installments. The RSUs vest over a three-year period, with one-third vesting on each of the first, second, and third anniversaries of the grant date. Dr. Magovevi-Liebisch will also receive annual compensation and annual equity awards as further provided in the Policy. A description of the Policy is available in the Company's proxy statement filed with the Securities and Exchange Commission on April 15, 20

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated October 2 , 2024 . 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. QUANTERIX CORPORATION By: /s/ Vandana Sriram Vandana Sriram Chief Financial Officer Date: October 3, 2024

View Full Filing

View this 8-K filing on SEC EDGAR